Chongqing Qiantai Biopharmaceutical Co., Ltd.

Chongqing Qiantai Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of BrightGene Bio-Medical Technology (Suzhou) Co., Ltd., a company listed on the STAR Market. It focuses on the research and development, registration, and production of microbial drug APIs and nano-iron APIs. The company's products involve therapeutic areas such as anti-tumor, anti-fungal infection, anti-bacterial drug-resistant infection, and immunosuppressants. It has completed the R&D of more than 30 products, with over ten products commercialized. Products such as caspofungin and micafungin have been launched in China; two technologies have been exported to Europe; more than 40 national invention patents have been applied for, with over 20 authorized; it has repeatedly passed the review for high-tech enterprise status and holds honors such as Chongqing Enterprise Technology Center and Chongqing Gazelle Enterprise. The company currently has more than 80 employees, including 70 R&D personnel, more than 20 with master's degrees or above, and more than 10 with senior professional titles or above. The company possesses over 300 sets of equipment including fully automatic fermentation tanks, ceramic membranes, ultrafiltration, nanofiltration, freeze dryers, HPLC, UPLC, LC-MS, GC, etc., meeting the needs of product development and registration. The parent company, BrightGene Bio-Medical Technology (Suzhou) Co., Ltd. (stock code: 688166), is a research-driven high-tech pharmaceutical company dedicated to the R&D and production of original new drugs and high-end generic drugs, providing patients with high-value products through professional product development and commercialization capabilities. With the goal of "continuous innovation, protecting health," BrightGene Pharmaceuticals seeks solutions for unmet clinical needs. After years of continuous R&D and exploration, BrightGene Pharmaceuticals has made breakthroughs in the fields of targeted therapy and immunotherapy for tumors, as well as in the treatment of fatty liver and diabetes, with multiple original new drugs entering or about to enter clinical research. BrightGene Pharmaceuticals has successfully developed high-end generic drugs such as caspofungin, micafungin, eribulin, trabectedin, and fondaparinux sodium, establishing product lines with global competitive advantages in areas such as anti-tumor, super antibiotics, and intravenous iron supplementation. Chongqing Qiantai Biopharmaceutical Co., Ltd. takes "making good medicines for health" to benefit society as its mission, providing customers with high-quality products and technical services through professional product R&D capabilities, and developing the company into a competitive, innovative, professionally capable, and excellence-seeking high-level drug R&D enterprise under BrightGene.